在斋月期间SGLT2抑制剂对2型糖尿病患者功能的影响:系统性审查
Muhammad Aamir Waheed1, Salah Ali Saleh Diffala Suwileh2, Khalid Rashid3
1College of Medicine, Hamad General Hospital, Qatar University, Doha, Qatar *Email: mawaheedhmc@yahoo.com.
Qatar medical journal
|July 22, 2024
概括
在斋月禁食期间,-葡萄糖共运输体2 (SGLT2) 抑制剂对2型糖尿病的穆斯林患者是安全的. 它们的使用在禁食期间不会显著影响功能 (eGFR).
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- SGLT2 抑制剂具有透性利尿性质.
- 在斋月期间禁食的2型糖尿病穆斯林患者可能面临体积枯竭和功能障碍的风险.
- 这项研究调查了在斋月期间使用SGLT2抑制剂对脏的影响.
研究的目的:
- 系统地审查SGLT2抑制剂对遵守斋月禁食的2型糖尿病患者功能的影响.
- 评估估计的膜过率 (eGFR) 和肌水平的变化.
主要方法:
- 对受控研究的系统审查 (2013-2023) 来自PubMed,EMBASE和Cochrane.
- 纳入标准:使用SGLT2抑制剂,2型糖尿病,斋月禁食和功能结果 (肌素或EGFR).
- 来自两项前性观察性研究的数据,涉及359名参与者.
主要成果:
- 在斋月期间使用SGLT2抑制剂并没有导致显著的eGFR变化.
- 哈萨内因和其他人. 研究:平均eGFR变化为-1.2±19.4 (SGLT2i) 与3.1±14.8 (非SGLT2i) 相比,p=0.06.
- 肖等人. 肖和其他人. 研究:最小平方平均eGFR变化为 -6.0 ± 1.5 (SGLT2i) 与 -4.2 ± 1.6 (非SGLT2i) 相比,p=0.39.
结论:
- 有限的观察数据表明,SGLT2抑制剂在斋月期间对2型糖尿病患者是安全的.
- 尽管SGLT2抑制剂具有利尿作用,但没有观察到对功能的显著影响.
- 需要对更大的队列进行进一步的研究来证实这些发现.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180
Oral Hypoglycemic Agents: Biguanides and Glitazones
186
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
186
Glucose Transporters
22.6K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.6K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
168
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
168
Oral Hypoglycemic Agents: Glinides
151
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
151
Oral Hypoglycemic Agents: Sulfonylureas
199
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
199


